Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 4Myasthenia Gravis 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Erythroblastic, Acute 1Leukemia 1

Interventions

Doxorubicin 310-propargyl-10-deazaaminopterin 3Vincristine 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Gemcitabine 2Drug Therapy 2Cyclophosphamide 2Alemtuzumab 2romidepsin 1cc-486 1belinostat 1Vitamin B 12 1Stem Cell Transplantation 1Standard of Care 1Specimen Handling 1Prednisone 1Practice Guidelines as Topic 1Melphalan 1Magnetic Resonance Spectroscopy 1Leukapheresis 1Hematopoietic Stem Cell Mobilization 1Folic Acid 1Etoposide 1Cytarabine 1Cladribine 1Carmustine 1Busulfan 1Brentuximab Vedotin 1Biopsy 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, T-Cell × Cladribine × Clear all
NCT05466318 2022-07-25

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Sichuan University

Phase 3 Unknown
306 enrolled
Lymphoid

Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡